Search results
Results From The WOW.Com Content Network
Micrograph of a Hurthle cell neoplasm. Hurthle cell thyroid cancer is often considered a variant of follicular cell carcinoma. [3] [4] Hurthle cell forms are more likely than follicular carcinomas to be bilateral and multifocal and to metastasize to lymph nodes. Like follicular carcinoma, unilateral hemithyroidectomy is performed for non ...
Histopathology of NIFTP, H&E stain. [1]Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor that was previously classified as an encapsulated follicular variant of papillary thyroid carcinoma, [2] necessitating a new classification as it was recognized that encapsulated tumors without invasion have an indolent behavior, [2] and may ...
Diagnosis is often based on ultrasound and fine needle aspiration. [1] Screening people without symptoms and at normal risk for the disease is not recommended. [10] [11] Treatment options may include surgery, radiation therapy including radioactive iodine, chemotherapy, thyroid hormone, targeted therapy, and watchful waiting. [1]
Thyroid neoplasm is a neoplasm or tumor of the thyroid. It can be a benign tumor such as thyroid adenoma, [1] or it can be a malignant neoplasm (thyroid cancer), such as papillary, follicular, medullary or anaplastic thyroid cancer. [2] Most patients are 25 to 65 years of age when first diagnosed; women are more affected than men.
Thyroid follicular adenoma ranges in diameter from 3 cm on an average, but sometimes is larger (up to 10 cm) or smaller. The typical thyroid adenoma is solitary, spherical and encapsulated lesion that is well demarcated from the surrounding parenchyma. The color ranges from gray-white to red-brown, depending upon the cellularity of the adenoma
The Organization recognized two subtypes of ISLN: in situ follicular neoplasia (ISFN) and in situ mantle cell neoplasia (ISMCL). [1] ISFN and ISMCL are pathological accumulations of lymphocytes in the germinal centers and mantle zones , respectively, of the follicles that populate lymphoid organs such as lymph nodes .
The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant. The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
[7] [8] HBME-1 staining may be useful for differentiating papillary carcinomas from follicular carcinomas; in papillary lesions it tends to be positive. [9] Reduced expression of ATP5E is significantly associated with the diagnosis of papillary thyroid cancer and may serve as an early tumor marker of the disease. [10]